2021
Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia
Kachuri L, Jeon S, DeWan AT, Metayer C, Ma X, Witte JS, Chiang CWK, Wiemels JL, de Smith AJ. Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia. American Journal Of Human Genetics 2021, 108: 1823-1835. PMID: 34469753, PMCID: PMC8546033, DOI: 10.1016/j.ajhg.2021.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBlood PlateletsCase-Control StudiesChildFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLymphocytesMaleMendelian Randomization AnalysisMiddle AgedMonocytesNeutrophilsPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisProspective StudiesQuantitative Trait LociUnited KingdomConceptsTrait-associated variantsMulti-trait GWASBlood cell homeostasisWide association studyGenetic risk lociTrait variationHematologic traitsRisk lociAssociation studiesCell typesGenetic determinantsLociInfluence susceptibilityUK BiobankMendelian randomization analysisGWASEtiological relevanceRandomization analysisTraitsHomeostasisSusceptibilityAcute lymphoblastic leukemia
2020
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literature
2019
Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.Peer-Reviewed Original ResearchConceptsBone-modifying drugsSupportive careMultiple myelomaInfluenza vaccinationAntiviral prophylaxisOlder adultsLower oddsEnd Results-Medicare databaseNon-Hispanic black patientsMultivariable logistic regression modelBaseline renal impairmentSupportive care useTreatment-related toxicityFacility-level characteristicsNon-Hispanic blacksOutcomes of interestCommunity-based settingsLogistic regression modelsRenal impairmentActive treatmentBlack patientsCare useConcomitant useProphylactic antiviralsReduced oddsIncreased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology
Nielsen AB, Zhou M, de Smith AJ, Wang R, McCoy L, Hansen H, Morimoto L, Grønbæk K, Johansen C, Kogan SC, Metayer C, Bracci PM, Ma X, Wiemels JL. Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. Haematologica 2019, 104: e514-e516. PMID: 30923090, PMCID: PMC6821599, DOI: 10.3324/haematol.2019.216465.Peer-Reviewed Original ResearchImpact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2018, 34: 1-15. PMID: 30314642, DOI: 10.1016/j.blre.2018.09.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCase ascertainmentAllogeneic hematopoietic stem cell transplantationAnnual age-adjusted incidenceHematopoietic stem cell transplantationOutcomes of patientsAge-adjusted incidenceStem cell transplantationAcute myeloid leukemiaTraditional morphologic assessmentClassification of MDSVariable cytopeniasCell transplantationMyelodysplastic syndromePrior receiptInefficient hematopoiesisEffective therapyMale genderRisk factorsMyeloid leukemiaEpidemiological trendsTreatment decisionsMyeloid neoplasmsEpidemiological assessmentDiagnostic criteriaTemporal improvementOncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaOlder adultsCell lymphomaPopulation-based cohort analysisHigh-quality cancer careAnthracycline-containing regimenGuideline-adherent therapyHigh-volume providersNumber of patientsLook-back periodCytotoxic regimensSystemic therapyImproved survivalClinical outcomesReduced hospitalizationsLymphoma patientsCancer careCohort analysisMedicare beneficiariesComplex surgeryDLBCL casesLymphomaClinical volumeCounseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8: 55. PMID: 29891916, PMCID: PMC5995881, DOI: 10.1038/s41408-018-0081-8.Peer-Reviewed Original Research
2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.Peer-Reviewed Original Research
2016
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 2016, 123: 449-458. PMID: 27690182, PMCID: PMC5297986, DOI: 10.1002/cncr.30325.Peer-Reviewed Original ResearchConceptsPatient respondentsPhysician respondentsTreatment goalsPhysicians' self-reported practicesProportion of patientsImportant treatment goalSatisfaction of patientsPatient-physician communicationPrognostic risk classificationSelf-reported practicesThrombotic eventsCommon symptomsSymptom improvementPatient recollectionSymptom assessmentPatients' perceptionsPatient educationDelay progressionImportant symptomPatientsRisk classificationSymptomsDisease managementLandmark surveyOne-third
2012
HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk
Urayama KY, Chokkalingam AP, Metayer C, Ma X, Selvin S, Barcellos LF, Wiemels JL, Wiencke JK, Taylor M, Brennan P, Dahl GV, Moonsamy P, Erlich HA, Trachtenberg E, Buffler PA. HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk. Blood 2012, 120: 3039-3047. PMID: 22923493, PMCID: PMC3471514, DOI: 10.1182/blood-2012-01-404723.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChildChild, PreschoolFemaleGenetic Predisposition to DiseaseGenetic VariationGenotypeHispanic or LatinoHLA-DP alpha-ChainsHLA-DP beta-ChainsHumansImmunologic FactorsInfantMalePrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRisk FactorsWhite PeopleYoung AdultConceptsAcute lymphoblastic leukemiaImmune modulationChildhood acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemia riskAcute lymphoblastic leukemia riskEarly immune modulationHuman leukocyte antigen (HLA) genesLowest exposure categoryLogistic regression analysisEtiology of childhoodNon-Hispanic whitesHLA-DPB1 geneRace/ethnicityInfectious exposureLymphoblastic leukemiaImmune mechanismsExposure categoriesHispanic ethnicityLeukemia riskGenetic susceptibility lociHLA-DPA1Immune systemHispanic childrenRegression analysisEvidence of interactionEpidemiology of Myelodysplastic Syndromes
Ma X. Epidemiology of Myelodysplastic Syndromes. The American Journal Of Medicine 2012, 125: s2-s5. PMID: 22735748, PMCID: PMC3394456, DOI: 10.1016/j.amjmed.2012.04.014.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeIncidence of MDSBetter risk-stratify patientsClonal hematopoietic stem cell malignanciesHematopoietic stem cell malignanciesRisk-stratify patientsStem cell malignanciesMore effective treatmentsMDS prognosisDifferent comorbiditiesPrognostic factorsSignificant morbidityEtiologic factorsDisease burdenPoor survivalEffective treatmentCell malignanciesHigh mortalityNew casesHeterogeneous groupComorbiditiesSyndromeDiseaseRecent studiesPotential interactions
2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Ma X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes & Control 2011, 22: 623-629. PMID: 21287258, PMCID: PMC3086405, DOI: 10.1007/s10552-011-9735-6.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesSurvival of patientsRisk of deathMyelodysplastic syndromeMDS survivalLifestyle factorsMultivariate Cox proportional hazards modelHigh-risk myelodysplastic syndromeCox proportional hazards modelLow-risk patientsProportional hazards modelInitial clinical encounterClinical characteristicsHazard ratioIndependent predictorsPrognostic roleMDS patientsCigarette smokingPoor survivalHematological malignanciesElevated riskHazards modelPatientsSmokingClinical encounters
2009
Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Sue LY, Schairer C, Ma X, Williams C, Chang SC, Miller AB, McCarty CA, Willcox BJ, Ziegler RG. Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 2842-2850. PMID: 19843674, PMCID: PMC2783562, DOI: 10.1158/1055-9965.epi-09-0087.Peer-Reviewed Original ResearchConceptsFood frequency questionnaireOvarian Cancer Screening Trial (PLCO) cohortPostmenopausal breast cancerBreast cancerEnergy intakeTrial cohortDietary assessmentIncident breast cancerBody mass indexBreast cancer riskFirst food frequency questionnaireLower energy intakeModest positive associationMultivariate RRsFrequency questionnaireHighest quartileMass indexLowest quartilePhysical activitySimilar riskCancer riskHuman studiesAge 55CancerAnimal experiments